Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

“Breakthrough Therapy” Development Speed May Be Tempered By Manufacturing Hurdles

Executive Summary

Sponsors and FDA also will have to work through issues related to companion diagnostics to prevent treatments designated under the FDASIA’s new expedited development pathway from being delayed. Harmonization with foreign regulators is essential to making the pathway work, stakeholders say.

Advertisement

Related Content

When Seeking ‘Breakthrough’ Status, Beware Of Manufacturing Changes
FDA ‘Expedited Review’ Would Shave Off Additional Month For Some ‘Breakthrough’ Products
FDA ‘Expedited Review’ Would Shave Off Additional Month For Some ‘Breakthrough’ Products
Merck’s HCV Combo Will Test FDA’s ‘Breakthrough’ Rescission Process
CDER Office of Pharmaceutical Quality Launches; Initial Impact On Manufacturers Is Minimal
Lessons From Avastin: Accelerated Approval Needs “Easy On, Easy Off” Mechanism, Pazdur Says
Redefining Accelerated Approval Criteria Would Expand Pathway’s Use, Panel Says
Industry Wants A Breakthrough Therapy, Even Without All The Standards
“Breakthrough” Designation Another Harmonization Opportunity, Woodcock Says
Expedited Approval Pathway Concept Draws Strong Support But Different Proposals

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS054913

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel